Home » Newsletters » BioWorld Science

BioWorld Science

March 13, 2019

View Archived Issues

Sig1R identified as upstream modulator of canonical autophagy

Stemline licenses worldwide rights to novel RET kinase inhibitor

Discovery and characterization of a novel CCK-1R agonist, NN-9056

CARD9 pathway as a potential therapeutic target in allergic airway disease

First subject dosed in phase IIb/III study of TD-1473 in patients with ulcerative colitis

Lipocine presents topline results from 16-week liver fat imaging study of LPCN-1144

Not just for cancer anymore, CAR T cells tested in lupus

Discovery of selective and potent arylpiperazine-based DHFR inhibitors for toxoplasmosis treatment

Novartis initiates phase II study of MIJ-821 in patients with treatment-resistant depression

Design of tricyclic indazoles as selective ER degrader antagonists for ERalpha+ breast tumors

Servier and Oncodesign enter LRRK2 inhibitor R&D collaboration

PANK4 gene mutation tied to congenital posterior cataract

FDA approves Rocklatan to reduce IOP in open-angle glaucoma or ocular hypertension

Positive interim results reported from phase II study of NBI-74788

Bristol-Myers Squibb discovers new Toll-like receptor 7 agonists

Researchers describe TFEB as a potential therapeutic target for AMD

AbbVie discloses Mcl-1 inhibitors

Friedrich-Alexander-Universitaet Erlangen-Nuernberg and collaborators patent MOR agonists

The University of Texas, Chempartner present ATR kinase inhibitors

New aryl hydrocarbon receptor antagonists identified at Kyn Therapeutics

Design of novel transgenic pancreatic adenocarcinoma mouse model

New mouse model of multiple sclerosis points to NLRX1 as a treatment target

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...